Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy
Key facts
- Who runs it
- University of Cologne
- Where
- Denmark, Germany, Netherlands, and Spain4 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 24 Jan 2025
- Planned end
- Jun 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Intervention group /arm 1 (Cataract surgery alone)
- Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)
- Record updated
- 21 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Patients with FECD and nuclear cataract in study eye
- Male and female patients ≥18 years of age
- Subject must be able to understand and read the national language
- Written informed consent prior to any study-related procedures
- Nuclear opalescence (NO) grades 2 and 3 according to the lens opacities classification system III (LOCS III)
- Krachmer grade (3 [2-5 mm diameter area with confluent guttae]; 4 [ > 5 mm diameter area with confluent guttae] without edema identified by slit lamp examination)
- Central corneal thickness (CCT) measured with Pentacam below 620 µm between 8:00 am and 01:00 pm
- BCVA logMAR < 0,7 and > 0,1
- No previous cataract surgery or triple-DMEK on the opposite side
- Pentacam quality specification: "OK"
- For women below age of 60 negative urine pregnancy test
Who cannot take part
- Iris synechiae, pupil diameter <6 mm after dilatation, pseudoexfoliation syndrome, subluxated lens, previous history of ocular trauma/surgery or inflammatory disease
- Systemic use of Alpha-1-Adrenozeptor-Antagonists, immunosuppressive therapy or chemotherapy
- Patients with ocular and/or systemic comorbidity affecting vision or clinically proven anterior and/or posterior segment disease other than FECD and cataract (exclusion of macular disease or edema by OCT)
- Subjective diurnal changes in visual acuity with worse visual acuity in the morning
- Corneal (epithelial) edema visible at slit lamp examination
- Preoperative anterior chamber depth below 2 mm
- Participation in other interventional trials parallel or within the last 4 weeks
- Pregnant women and nursing mothers
- Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator
- Legally incapacitated persons
- Persons held in an institution by legal or official order
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to investigate whether there is a difference in BCVA in patients who receive one of the following two surgeries: intervention group (arm 1) cataract surgery alone and control group (arm 2) cataract surgery combined with removal of the diseased endothelial cells and the attached Descemet's membrane followed by transplantation of a healthy endothelial cell layer with attached Descemet's membrane ("triple-DMEK" group; comparator therapy).
Read full original descriptionShow less
The secondary objectives are to compare the two surgical methods with regard to other visual functions and optical as well as morphological differences, to safety, to quality of life, and to safety.
The 2 groups in the trial
- Experimental intervention /arm 1Treatment being tested
After randomisation the investigational therapy (arm 1), patients undergo a cataract surgery with preservation of the diseased endothelial cells. The cataract surgery will take approximately 10-20 minutes. The follow-up period after surgery will be 22 weeks ± 14 days.
Treatment: Intervention group /arm 1 (Cataract surgery alone)
- Control intervention /arm2Other group
After randomisation, patients in the comparator therapy (arm 2) undergo triple-DMEK which is a cataract surgery combined with DMEK (removal of the diseased endothelial cells followed by transplantation of a healthy endothelial cell layer). Triple-DMEK takes approximately 5-10 minutes longer than cataract surgery. The follow-up period after surgery will be 22 weeks ± 14 days.
Treatment: Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- European Prospective Multicentre Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy (ETCF-trial)
- Record updated
- 21 February 2025